Arcus Biosciences (RCUS) FCF Margin (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly FCF Margin came in at 811.76% in Q1 2026, down 33676.0% year-on-year from N/an in Q1 2025, and down 121.39% quarter-over-quarter from 366.67% in Q4 2025.
Arcus Biosciences (RCUS) FCF Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' FCF Margin history runs 10 years deep, the most recent figure standing at 811.76% for Q1 2026.
- On a quarterly basis, FCF Margin fell 33676.0% year-over-year to 811.76% in Q1 2026; TTM through Mar 2026 was 207.2%, a 1004.0% decrease from a year earlier, with the FY2025 full-year figure at 195.95%, down 13859.0% from the prior year.
- FCF Margin slipped to 811.76% in Q1 2026 per RCUS's latest filing, from 366.67% in the prior quarter.
- Across five years, FCF Margin topped out at 3616.67% in Q1 2022 and bottomed at 811.76% in Q1 2026.
- The 5-year median for FCF Margin is 248.72% (2024), against an average of 73.72%.
- Across the five-year window, FCF Margin surged 434703 bps in 2022 and plunged 404067 bps in 2023, its largest moves.
- Year by year, FCF Margin stood at 211.76% in 2022, then slumped by 237 bps to 714.29% in 2023, then soared by 49 bps to 361.54% in 2024, then retreated by 1 bps to 366.67% in 2025, then slumped by 121 bps to 811.76% in 2026.
- Per Business Quant, the three latest RCUS FCF Margin figures stand at 811.76% (Q1 2026), 366.67% (Q4 2025), and 373.08% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Arcus Biosciences | 3.57 Bn | 2.75 Bn | - | -811.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -811.76% |
| Dec 31, 2025 | -366.67% |
| Sep 30, 2025 | -373.08% |
| Jun 30, 2025 | -83.13% |
| Mar 31, 2025 | -475.00% |
| Dec 31, 2024 | -361.54% |
| Sep 30, 2024 | 95.83% |
| Jun 30, 2024 | -248.72% |
| Mar 31, 2024 | -2.07% |
| Dec 31, 2023 | -714.29% |
| Sep 30, 2023 | -209.38% |
| Jun 30, 2023 | -196.55% |
| Mar 31, 2023 | -424.00% |
| Dec 31, 2022 | -211.76% |
| Sep 30, 2022 | -254.55% |
| Jun 30, 2022 | -233.33% |
| Mar 31, 2022 | 3,616.67% |
| Dec 31, 2021 | -17.01% |
| Sep 30, 2021 | -621.85% |
| Jun 30, 2021 | -747.70% |